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ABSTRACT 
 
Cancer remains a problem worldwide as one of the leading causes of morbidity and mortality. 
Many cancer patients experience recurrence and ultimately death due to treatment failure or 
the development of chemoresistance. The concept of chemoresistance however is complex, 
recent studies have highlighted that cellular structure and extra-cellular composition, 
mechanics and structure play a role in the development of chemoresistance.  The mechanical 
properties of cells impact their architecture, migration patterns, intracellular trafficking and 
many other cellular functions. Studies have also revealed that cellular mechanical properties 
are modified during cancer progression. We investigated these mechanical properties and 
changes to them by using a malignant melanoma cell line (WM1158) and a chemoresistant 
malignant melanoma cell line (SK-MEL29). Malignant melanoma was the cell line of choice as 
it is one of the most prominent types of cancer known to develop chemoresistance. The aim 
of this study was to identify the effects of chemotherapeutic drug exposure on the mechanical 
properties and cytoskeletal composition of drug sensitive and drug resistant malignant 
melanoma cells. To achieve this, a combination of Multiple particle tracking microrheology 
(MPTM), quantitative RT-PCR and Western blotting techniques were utilised to demonstrate 
changes in cytoskeletal elements that are responsible for cellular mechanics. MPTM was 
developed as an approach to map intracellular mechanical properties of living cells and track 
the intracellular particles by Brownian motion to establish a viscoelastic model and compare it 
with the power-law approach. A quantification of the MPTM allowed capturing of the cell 
stiffness using the mean squared displacement (MSD) of cell under different conditions. The 
cytoskeletal elements actin and β-tubulin were analysed in qRT-PCR and Western blot as they 
form the key elements governing a cell’s mechanical stability and response to mechanical 
stimuli. The findings from this study revealed cell stiffness decreases as cancer progress, 
thereby cells become stiffer. The same pattern was evident for chemoresistant malignant cells 
and revealed that they had a loss of elasticity in comparison to their counter non-resistant 
malignant cells. With regards to protein levels and mRNA expression, the chemotherapeutic 
drug affected the cytoskeleton causing cells to undergo morphological changes which, 
however, was not seen in chemoresistant cells. The results from this study indicated that 
measuring mechanical properties of cells provides an efficient marker for cancer diagnosis 
and deeper understanding of cancer mechanobiology. 
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CHAPTER 1: Literature Review 
 
1.1 Introduction 
Cancer remains a major burden worldwide as one of the leading causes of morbidity and 
mortality. In 2012, approximately 14 million new cases were recorded with an estimate of 8 
million deaths occurring due to cancer (1, 2). The burden of cancer is projected to increase 
over the next few years to reach an estimated 22 million new cases and 13 million deaths 
related to cancer by 2030 (1, 3). Although the burden of cancer can be seen on a global scale 
and subsequently developing countries tend to suffer greatly due to limited resources. Cancer 
however falls under chronic, non-communicable disease which forms part of a larger 
epidemiological transition. In addition to the associated cancer risk factors for example diet, 
tobacco, alcohol, lack of exercise, and industrial exposures, developing countries are 
burdened by cancers which are attributable to infectious diseases (3). Recent studies have 
indicated of the total deaths recorded per day due to cancer, over two thirds occur in 
economically developing countries (1, 4).  
The management of cancer is complex, with chemotherapy being one of the standard 
treatment methods of choice, due to its ability to target local tumours, as well as metastasizing 
cancers. Chemotherapy is used based on its ability to induce cell death in tumours, however 
many cancer patients experience recurrence and ultimately death due to treatment failure (5, 
6). This is caused by a phenomenon known as chemoresistance. This concept was first 
presented when bacteria became resistance to certain antibiotics, since then cancer cells have 
been presenting with a similar mechanism (4, 6, 7). This concept however is far more complex 
than previously thought, recent studies have highlighted that cellular structure and extra-
cellular composition, mechanics and structure play a role in chemoresistance.   
 
This literature review will establish a theoretical framework and provide a general overview of 
the key areas of this research pertaining to this thesis. 
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1.2 Cancer  
1.2.1 Cancer Defined 
Cancer is a collection of distinct illnesses that result due loss of control in normal cell growth 
patterns (neoplasia) in the human body leading to abnormal cell development. Normal cells 
are constantly subject to signals that dictate whether the cell should divide, differentiate into 
another cell type or die. Cancer is usually caused by mutations in the DNA that activate 
oncogenes, trigger genetic instabilities or silence tumour suppressor genes (8-11). Under 
normal conditions cells are able to detect and repair damaged DNA strands. If the damage is 
too severe and cannot be repaired, the cell with undergo apoptosis (programmed cell death) 
(10, 12). Previously cancer had been associated with an increase in cell number or mutations 
leading to alterations in regulation of cell production or proliferation mechanism. However in 
certain cancer types it is caused by decreased apoptotic rates (10).  
 
These abnormal cells are known as tumour cells and are best described as cells that are not 
responsive to normal growth –controlling mechanisms (13, 14). As tumour cells develop and 
accumulate, they form masses or lumps known as neoplasms. This neoplastic growth process 
can be a rapid or slow process (weeks or even years) to develop. The exact growth rate has 
not yet been established and depends on the type of cell or tissue involved. The tissue 
pathology varies greatly in the detection from normal tissue, some are obvious and easily 
visualized, while others are difficult and not that easy detected (8, 9, 15). However, the key 
element to look out for is an abnormal cell nucleus as the nucleus is the main characteristic 
feature of a cell and the genetic make-up (DNA) of the cell. There are different stages in cancer 
development and not all tumours are found to be cancerous.  An illustration of normal, benign 
and malignant cells can be seen in Figure 1 below. 
 
 
Figure 1: Different stages of cancer: A histological illustration of normal cells, benign cell and 
malignant tumour cells, expressing abnormal cell nucleus as described previously, with permission 
from (16).  
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1.2.2 Types of Tumours 
Benign tumours are non-cancerous localised lesions. They are usually small, not reaching 
larger than 5 cm in diameter. They are also known to be superficial with about only 1% of 
these lesions being deep (17, 18). Benign tumours have a non-invasive characteristic, 
therefore when they arise in tissues such as epithelial or mucosal; they grow outwards away 
from the tissue surface. This outwards growth resembles a polyp which may be either sessile 
or stalked. Even though these tumours are not capable of spreading or invading other organs 
or parts of the body, they can be dangerous and cause clinical problems (17-19). These 
problems are usually caused by fluid flow obstruction (e.g. benign epithelial tumour arising in 
a duct) or pressure on adjacent tissues (e.g. benign meningeal tumours causing epilepsy). 
Benign tumours are usually treated by surgical removal and are therefore non-recurring (18).  
Malignant tumours however are cancerous lesions and found to be larger and deeper than 
benign tumours. They are significant in that they are fast growing and have the ability to invade 
their surrounding tissues (18-20). The fact that these types of tumours can metastasize to 
other parts of the human body and colonize these distant organs makes them malignant 
(cancerous). The type of tumour that forms depends on the type of cell that was initially altered 
(19, 20). There are four types of tumours: 
1. Carcinomas - result from altered epithelial cells.  
2. Sarcomas - result from changes in muscle, bone, fat, or connective tissue. 
3. Lymphoma – a cancer of the lymphatic system cells that derive from bone marrow. 
4. Myelomas - cancers of specialized white blood cells that make antibodies. 
 
A tumour can be classified as “cancer” or “malignant” once it has invaded surrounding tissue 
known as metastasis (12, 21). 
 
 
1.2.3 Cancer Genetics 
Cancer is said to be genetic disease, as it is caused by mutations in critical cancer-susceptible 
genes (22, 23). Even though other aspects such as environmental factors (carcinogens) or 
non-genetic factors play a role in many stages of cancer development, a mutation has to occur 
for a cell to become cancerous (24). Human genes are found in the DNA in each cell in the 
human body. They are responsible for normal functions of the cell such as, growth rate, 
proliferation and differentiation, and cell survival. Most of the mutations occur and are 
accumulated during the division of cells in the normal cell cycle process (25, 26). A mutation 
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in one gene however is not sufficient for cancer to develop, multiple mutations are necessary 
for abnormal cells to become cancerous (27). 
 
Cancer has a large genetic component to it; this is because cancer arises from alteration or 
changes in the DNA of normal cells or by transcriptional or translational processes that then 
produce mutations in gene expression (27, 28). Genetic changes responsible for the increased 
risk in cancer development may occur as either a germline and/or a somatic event. Not all 
cancers are hereditary (genetically inherited), however over 200 hereditary cancer syndromes 
have been described to date. Germline mutations are inherited genetic changes from an 
individual’s parents that have the mutation present in their germ cells (29, 30). These are the 
reproductive cells of the body such as ova and sperm and the mutation will be present in every 
cell of the offspring. These individuals are at a higher risk of certain predisposing malignancies 
and the risk is even greater if multiple members of the family is afflicted (26, 28). 
 
Somatic mutations are acquired genetic changes occurring during an individual’s lifetime and 
therefore not from genetic inheritance. They arise due to minor sequence changes leading to 
activation or inactivation of certain gene functions and gene expression or due to exposure to 
DNA damaging carcinogens (29, 31, 32). The mutations caused by activation that result in the 
foundational stages of carcinogenesis are found to be mostly somatic events. This type of 
event can be referred to as an event or mutation caused by some sort of outer stimuli such as 
environmental factors or carcinogens (28). Even though most of the mutations are caused by 
somatic events; both types of mutations occur in the cancer-susceptible genes. These genes 
are classified as oncogenes and tumour suppressor genes (23, 30, 32). 
 
1.2.3.1 Proto-oncogenes 
The process whereby cells undergo maturation, differentiation and apoptosis occurs in an 
orderly fashion. The process is essential in normal human development and also for 
maintaining the structure and composition of organs and tissues (33). This process is tightly 
regulated by the genes known as proto-oncogenes. Proto-oncogenes can be found within a 
cell’s nucleus and code for proteins that assist in cell growth regulation. They promote cell 
growth by contributing to signalling pathways, these pathways are responsible for relaying 
growth stimulating signals to the cell’s nucleus. Proto-oncogenes communicate these signals 
by a means of intracellular biochemical signals functioning in a cascade (34, 35). This process 
then results in the activation or repression of certain specific genes. 
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Proto-oncogenes operate as a positive growth regulator and a mutation in these genes results 
in a different protein being produced, which in turn interferes with the normal regulation of cells 
(35, 36). Once the developmental process is completed which they regulate, their activities 
are then inactivated. If their activity remains at a high or they are later in life inappropriately 
activated they become mutated. Proto-oncogenes are targets for potential mutations due to 
their location often being near the breakpoints on chromosomes (35). This leads to them 
having an increased probability of becoming activated and mutated.  
 
1.2.3.2 Oncogenes 
Oncogenes are the mutated form of proto-oncogenes and their inheritance is found to be 
dominant in nature. A mutation or translocation in a proto-oncogene activates it to evolve into 
an oncogene; the transcription produces proteins encoded for by the oncogenes. These 
proteins are  either increased or an alteration occurs in the protein itself changing its structure 
or function (37). This increase or alteration then leads to a decrease in cell differentiation, 
increase in cell division and an inhibition of cell death  therefore resulting in a gain in function 
(33). Mutations or translocations occur as initiating events for tumour development or during 
the progression stages, whereas the amplification of oncogenes takes place only during the 
progression of tumours (38).   
Each oncogene is closely associated with the normal DNA sequence found in the cellular 
genome. The conversion of proto-oncogenes to active oncogenes occurs via one of five 
mechanisms (39, 40). The first mechanism being due to the overexpression of proto-
oncogenes and occurs due to acquisition of a novel transcriptional promoter. The oncogene 
becomes active as their transcript production occurs at a higher level than those of normal 
proto-oncogenes. The second mechanism is over-expression and due to proto-oncogenes 
being amplified. The third mechanism is due to influences of transcription levels, thereby 
influencing the amount of gene product. Following chromosomal translocation, juxtaposition 
of oncogenes and immunoglobulin domains occurs, resulting in deregulation of the gene is 
known as the fourth mechanism. Lastly, activation can occur due to an alteration in the 
oncogene proteins structure (39-41). 
Upon activation of cellular oncogenes, the cell carrying the mutation develops a growth 
advantage or increased survival (39).  These activated oncogenes can represent one of two 
types of distinct genetic changes, these genetic alterations lead to either an increase in gene 
expression or an uncontrollable activity of the proteins encoded by the oncogenes (38, 41, 
42). The mechanism by which oncogenes are activated is diverse and includes the 
upregulated expression of gene products. It also includes the expression of mutant protein, 
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expressing enhanced stability, altered functionality, altered recruitment or subcellular 
localization of a normal gene product. This expression can be seen through the interaction 
with an aberrantly expressed or mutant binding protein partner (36, 41).  
 
 
Figure 2: Oncogene. An illustration of the process of oncogene activation from proto-oncogene to 
activation leading to cancer cells, with permission from (43). 
 
1.2.3.3 Tumour Suppressor Genes 
Tumour Suppressor Genes (TSG) also referred to as anti-oncogene, is a class of genes 
involved in the normal regulation of cell growth, but may become cancer-causing when 
damaged or inactivated (44-46). They encode for certain proteins that play a part in the 
inhibition of cell proliferation process. These proteins are crucial to the normal cell 
development and differentiation process, their products therefore negatively regulate cell 
growth. It does this by physically blocking the action of growth promoting proteins, thereby 
representing the opposite side of normal cell growth control (44, 46-48). These proteins 
therefore inhibit the cell proliferation process or survival and some have been seen to directly 
antagonize proto-oncogenes action in growth regulation (49). However, some of the tumour 
suppressor genes have been found to normally be active transcription factors within the 
nucleus of the cell.  
The function of TSG in the cell cycle is to induce checkpoints, pauses or arrests in certain 
stages of the cycle as needed. This function is to allow for the repair of DNA and acts to ensure 
that the cell’s genome integrity stays intact (42, 45, 50). Therefore, abnormal repression or 
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inactivation of the TSG is responsible for the deregulation of the cell cycle resulting in excess 
cellular proliferation by prolonging proliferation signals or cellular disorganisation. Because of 
this regression of TSG, tumour development is initiated via the elimination of negative 
regulatory proteins (50, 51). This ability leads to the uncontrolled growth of cancer cells and 
development of a cancerous tumour, due to the genetic damage or mutation. In some cases, 
TSG have been found to inhibit the same cell regulatory pathways that oncogenes products 
have stimulated (46, 50, 51).  
 
The difference between TSG mutations to other potential carcinogenic mutations is that the 
altered TSGs produce direct modifications in the protein products responsible for the 
transformed phenotype (46, 50, 51). Proto-oncogenes on the other hand produce indirect 
effects on the protein products. On a cellular level TSGs behave recessively however their 
inheritance is dominant in contrast to other cancer related genes. The suppression of TSGs 
occurs more frequently than the activation of oncogenes (51). Fully functional TSGs are able 
to supress tumour development even in the presence of active oncogenes. This indicates the 
importance of TSGs in the functionality and regulation of normal cells.  
 
It is now evident that oncogenes and TSGs play a critical part in the development of cancer 
due to their involvement in the activation and inhibition of the cell proliferation process (45, 
47). As mentioned previously cancer development is a multistep process in which normal cells 
or eukaryotes progress from benign to malignant. The complete sequence of events is 
however not known yet, but it is clear that the activation of oncogenes and inactivation of 
tumour suppressor genes are critical steps in tumour initiation and progression (45, 48, 51).  
Oncogenes and TSG cannot trigger cancer development by themselves and therefore jointly 
play a part in cancer development by combining their functions. Based on this, it is evident 
that cancer has a genetic component attached to it and can thereby be either inherited or 
caused by somatic mutations (44, 46, 48). 
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Figure 3: Tumour suppressor gene. An illustration of the difference between a normal TSG and a 
mutated TSG with their effects on cell division, with permission from (43).  
 
1.2.4 Tumour Biology 
Cancer develops from healthy cells in a complex process called malignant transformation. 
Cancerous cells are known to behave in an independent manner, with loss of growth control 
forming tumours, this process consists of a series of steps (52-54). The first step in the cancer 
development is termed Initiation. In this stage cells undergo hyperplasia, being an 
overproduction of cells due to uncontrolled cell division. Hyperplastic cells do not undergo any 
morphological changes and the cells appear normal just in excess amounts.  
The initiation phase is caused by change in the cells genetic material (DNA mutations) and 
may occur completely spontaneous or brought on by carcinogens (cancer causing agents) 
termed initiators (55, 56). Carcinogens bind covalently to DNA or macromolecules within the 
cell to cause the mutation. The genetic mutations are permanent damage and any daughter 
cells produced from the division of the mutated cell will carry forth the mutation.  
The second stage of cancer development is termed promotion and cells undergo dysplasia 
(52). Dysplasia results from further proliferation and the cells begin to undergo abnormal 
morphological changes. In order for this stage to take effect cells had to be mutated by an 
initiator, as promoters has no effect without an initiator (55). Promoters affect intracellular 
pathways that lead to increased cell proliferation by alternatively binding to receptors on the 
cells surface. 
In the third stage tumours start to take on form and are termed neoplasms or benign tumours. 
This process is termed progression and caused by additional changes to the cells (53, 55). 
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The cells morphological profile is even more disrupted and the cells spreading ranges over a 
wider area of the surrounding tissue. These tumours however are still contained within their 
original location and also known as “in situ” (53, 57). They are not malignant but considered 
potentially malignant. The cells of these tumours are termed anaplastic, due to the loss of their 
original function (57). The loss of original function is associated with karyotypic changes, 
causing all tumour cells to have an aneuploidy (incorrect chromosomal count) karyotype (55). 
This change is coupled with invasiveness and alterations in the cell’s biochemistry and 
morphology.   
The last step in the cancer development process is termed metastasis and cells are then 
considered malignant. In this stage cancerous cells break free from the original/primary tumour 
site and migrate to other locations in the body in a unidirectional way. The first stage of the 
metastasis process occurs when primary tumour cells start to invade the tissues surrounding 
the primary tumour (58, 59). These cells then acquire the correct capacity enabling then to 
evade the body’s immune defences. The cancer cells are then able to enter circulation. 
However, before the cancer cells leave their primary site, the primary tumour may have primed 
pre-metastatic sites. These sites are then more receptive of the arriving tumour cells (60, 61). 
These processes of tumour biology are depicted in Figure 4 below. 
 
Figure 4: Cancer Development. An illustration of the series of steps of malignant transformation, 
from initiation stage to metastases as explained above, with permission from (62). 
Cancer cells that have detached from their primary sites can metastasize (enter circulation) 
by either entering the bloodstream or the lymphatic system. Because these systems circulate 
all over the body it allows the cancer cells to be transported to distant anatomic locations away 
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from the original sites. Once the cancer cells enter these systems, they are able to leave the 
system and invade other tissue types if the conditions are favourable (59, 63, 64). Other tissue 
types that are easily invaded are tissues such as brain, lung, liver and bones. Cancers that 
have metastasised are secondary tumours and these cancers retain their name from the 
original cancer. Metastasis plays an important role in the determination of the staging of 
tumours as well as the treatment of cancers (58). 
 
1.3 Cell Mechanics 
1.3.1 Cell Mechanics Theory 
The cell is considered to be the basic structure and fundamental unit of life. The human body 
is made up of 50 to 100 trillion cells termed Eukaryotes meaning “true nucleus”. These cells 
are a well-organized system that makes up the elements of a fully functioning human body 
(65, 66). Cells are highly dynamic entities that are made up of a variety of components each 
with different biomechanical properties and characteristics. They are responsible for all the 
essential tasks such as replicating, respiring, eating and the excretion of waste products (67, 
68). In general, a cell consists of four major components being cellular membrane, cytoplasm, 
nucleus and organelles, as shown in Figure 5.  
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Figure 5: The eukaryotic cell. An illustration of the eukaryotic cell with its various components that 
make up its heterogeneity, including the important factors of the cytoskeleton used to determine 
mechanical properties of cell mechanics, with permission from (69). 
 
The cell membrane is the outermost part of the cell and is responsible for maintaining the cells 
integrity. The membrane is an extremely thin layer allowing the cell to be flexible and 
somewhat elastic. It also allows cells to communicate and interact with each other by receiving 
and responding to incoming messages (70). It is also responsible for many important 
metabolic reactions such as controlling the entry and departure of certain substances. The 
cytoplasm on the other hand is responsible for most of the cells activity and contains most of 
the cells organelles (71). The cytoplasm is made by biopolymer filaments such as actin, 
microtubules, and intermediate filaments, which together make up the cytoskeleton of the cell 
(70, 72). The cytoskeleton is the supportive framework and can be defined as “a spatially 
sparse tangled matrix of rods and rod-like elements held together by smaller proteins, which 
maintains the cell’s structure” (73).  
Cells are able to constantly remodel their internal structure in response to chemical and 
physical stimuli; this remodelling in turn affects their mechanical properties (74). The 
mechanical properties of a cell depend on the properties of the cytoskeleton and are described 
in terms of the cells strain response to applied stress or forces. These properties have been 
found to differ at different length and time scales. Several studies have been conducted to 
measure mechanical properties of the cytoskeleton with the focus as either using living cells 
or a reconstituted polymer network in vitro (mimicking the cell’s cytoskeleton) (75-78). Two 
different mechanical behaviours for cells have thereby traditionally been described by 
investigators and taken from engineering and physics and applied to biological systems, these 
are known as solid-like and liquid-like. A viscoelastic behaviour has also been defined for cells 
with both liquid-like and solid-like properties, which will be defined later in this literature review 
(69). 
 
1.3.2 Measurement of Cell Mechanical Properties 
Over the past 150 years, the study of cell mechanics has been a growing field of interest.  
Researchers have been motivated to develop an improved understanding of the structural and 
mechanical changes such as cell migration and metastasis, adherence or any simple 
response occurring due to various cellular environments that occur in cells during various 
biochemical and biological processes (79, 80). A variety of experimental methods have been 
developed over the years to find the mechanical properties of cells.  
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The most common technique utilised to date is probing of cells, in which a mechanical 
perturbation taking the form of either an applied force of deformation on the cell and allowing 
the cells dynamic responses to be investigated (81). By measuring cell deformations in 
response to force became the fundamental mechanism behind these approaches. Over the 
years a consensus has developed that on a large scale cells are soft viscoelastic materials, 
however at smaller length scales (< 1τ)  they are increasingly heterogeneous (79). Based on 
this previous statement the cell as a whole is considered to be predominately viscous at lower 
frequencies and more elastic at increased frequencies, nonetheless the exact frequency at 
which this transition occurs is unclear.  
Other techniques also exist such as deformation with micro-plates, micropipette aspiration, 
atomic force microscopy, magnetic traps and optical tweezers were later developed based on 
the same principle of deformation response to force (75).  Multiple global laboratories have to 
date successfully utilised these techniques for measuring cell mechanics, however many 
questions remain regarding the meaning and accuracy of findings by these methods (82).  
1.3.3 Microrheology for Cell Mechanics Measurement 
Microrheology collectively refers to a family of recently developed techniques to measure the 
viscoelastic properties of complex fluids and soft materials with relatively high temporal and 
spatial resolution (83, 84). It uses Brownian motion to assess viscoelasticity. Brownian motion 
describes the random movement of particles embedded in a system of molecules and is the 
backbone of particle tracking microrheology. This motion can be quantified and further used 
to study the mechanical properties of materials. Mechanical properties can be determined by 
tracking the motion of micron-sized particles embedded in a material. The techniques 
previously mentioned are known as active microrheology, these techniques use external 
forces to manipulate probe-particles. Passive microrheology however simply allows the 
particles to be driven by the thermal energy of the material. Passive methods have an 
advantage over active methods since no large strain or stress is applied to the cell and a linear 
response can be measured directly. This is particularly useful in soft materials and complex 
fluids where even a small-imposed strain can cause reorganization of structure within the 
material and thus change its viscoelastic properties (e.g., strain hardening or shear thinning) 
(85, 86). 
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1.3.3.1 Viscoelasticity  
Viscosity is a property of a material that describes the materials resistance to flow as a fluid 
under the application of a shear stress (stress is the average amount of force exerted per unit 
area). Elasticity however is thought of a measurement of deformation in solid material in 
response to an applied stress or strain. A viscous system is constituents such as Newtonian 
fluids (e.g. water, glycerol or oil) and is known to lose its shape and dissipate energy in 
response to a stress through viscous flow. A pure elastic system on the other hand contains 
solid constituents (e.g. rubber or a bouncing ball) that will retain energy and return to its original 
shape in a spring-like effect once the stress has been removed (75).  A viscoelastic material 
is therefore a complex material that displays both viscosity and elasticity. This principle is used 
to study mechanical properties in microrheology and measures complex systems such as cells 
in response to applied forces. 
 
1.3.3.2 Particle Tracking Microrheology 
Particle tracking microrheology (PMT) is a passive microrheology technique that measures 
the Brownian motion of particles to extract mechanical properties at small scales. This 
technique that allows for the collection and analyses of the displacement of tracer particles 
embedded within a medium (80). It is used to investigate viscoelastic properties and provide 
insight into the structural rearrangements of a wide range of materials, in particular soft 
materials and complex fluids like cell cytoplasm in living cells.  In passive microrheology, no 
force is applied; the particle displacement is in response only to spontaneous motion of tracer 
particles (79). This spontaneous motion deforms the medium in the vicinity of the particle. 
Brownian motion of the particles can then be taken with a light microscope of adequate 
resolution equipped with a CCD camera to capture a series of magnified video images.  
 
Utilising this technique the displacement of fluorescently labelled tracer particles in the 
medium due to thermal fluctuations can be measured (87). The video images are processed 
into time-dependant x-y particle trajectories. By using specialized image processing software 
and tracking routines, the particle trajectories can be used to quantify the amplitude of motions 
over different time scales by Brownian motion which is expressed as the Mean-Squared 
Displacement (MSD). The MSD of the particle’s trajectories is used to quantify its amplitude 
of motion over different time scales.  The particle trajectories data is of a stochastic nature and 
the particle dynamics needs to be statistically analysed. Transforming the particle trajectories 
into mean-squared displacement profiles provides a convenient way to quantitatively 
characterize this motion.  The MSDs are related to the particle trajectory according to  
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               〈∆𝑟𝑟2(𝑡𝑡)〉 = 〈[𝑥𝑥(𝑡𝑡 + 𝜏𝜏) − 𝑥𝑥(𝑡𝑡)] + [𝑦𝑦(𝑡𝑡 + 𝜏𝜏) − 𝑦𝑦(𝑡𝑡)]〉2     [1] 
 
 
 
In this equation t refers to position in time, and 𝜏𝜏 to the lag time between the particle positions. 
In the case of viscoelastic materials, MSDs scale nonlinearly with time according to a power 
law 
 
                           〈∆𝑟𝑟2(𝑡𝑡)〉 ~𝑡𝑡𝛼𝛼      [2] 
 
The power law exponent,𝛼𝛼, is a representative of the type of motion the particle undergoes. 
Particles may exhibit locally constraint solid-like motion (𝛼𝛼 = 0), sub-diffusive motion (0 < 𝛼𝛼 <1) at short time intervals, diffusive fluid-like motion (𝛼𝛼 = 1), or enter into the super diffusive 
regime (𝛼𝛼 > 2) at longer time intervals.  
The MSD can be computed using the tracer particles for each individual bead; once the MSD 
is determined, the generalized form of the Stokes-Einstein Relation (GSER) can be used to 
extract mechanical properties. Applying the algebraic approximation of the Generalized 
Stokes-Einstein Relation (GSER), the shear modulus of the medium can be calculated 
according to the following equation (83): 
 
  𝑮𝑮�(𝑠𝑠) = 𝑘𝑘𝐵𝐵𝑇𝑇
𝜋𝜋𝜋𝜋𝜋𝜋〈∆𝒓𝒓�2(𝜋𝜋)〉 = 𝑘𝑘𝐵𝐵𝑇𝑇𝜋𝜋𝜋𝜋〈∆𝑟𝑟2(𝑡𝑡)〉𝛤𝛤�1+𝜕𝜕ln〈∆𝑟𝑟2(𝑡𝑡)〉
𝜕𝜕 ln 𝑡𝑡
�
   [3] 
 
In this equation, 𝑮𝑮�(𝑠𝑠) is the shear modulus in the Laplace frequency domain, s, 𝑘𝑘𝐵𝐵 the 
Boltzmann constant, 𝑇𝑇 the temperature of the medium, 𝑎𝑎 the radius of the particle, and 𝛤𝛤 refers 
to the gamma function (83). By replacing the Laplace frequency with the 𝑖𝑖𝜔𝜔, the complex shear 
modulus can be expressed by: 
                                               𝐺𝐺∗(𝜔𝜔) = 𝐺𝐺′ + 𝑖𝑖𝐺𝐺′′      [4] 
 
In this substitute equation 𝐺𝐺′ and 𝐺𝐺′′ represents the storage and loss moduli, respectively. The 
amplitudes of the tracer particle motions are thereby inversely proportional to the material’s 
stiffness and directly related to the network's mechanical properties.   
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1.4 Chemotherapy 
1.4.1 Chemotherapy Explained 
Chemotherapy or cytotoxic medication is the use of medication or chemicals (such as aspirin 
or antibiotics) to treat diseases. Although it is more commonly known as the treatment for 
cancer and more than 100 chemotherapeutic drugs are available today. These therapeutic 
agents can either be used individually or in a combination to increase these treatment 
modalities effectiveness (88). These agents vary widely in their chemical composition, mode 
of action, effectivity for specific cancer types and side effects. In order to understand 
therapeutic effect of these medications, the progression of cancer and normal cell cycle 
need to be understood (89, 90). As described previously tumours are made up of cells 
that are reproducing at abnormally high rates. The normal eukaryotic cell knows when to 
inhibit reproducing (or dividing) when contact is made with other cells. Tumour cells 
nevertheless do not have this inhibitory mechanism causing cells to continue diving and 
replicating. The RNA or DNA of a cell tells it how to replicate itself, and classic 
chemotherapy (which excludes immunotherapeutic and biological response modifiers) 
works by penetrating the cell walls and destroying the RNA or DNA. The chemotherapeutic 
drugs effectiveness is increased by the replication rate of tumour cells and specific stage 
of the cell cycle.  
 
Cytotoxic medication works by causing destruction of cancer cells and preventing proliferation 
of cancer cells (88). The primary objective of using this treatment is to obtain an adequate 
exposure to cancer cells to obtain reasonable destruction while limiting the unacceptable 
toxicity to the normal functioning cells of the body (88, 90). Chemotherapy is the main 
treatment of choice for cancer patients, compared to radiotherapy, immunotherapy and 
surgery. It has been shown to produce more satisfactory benefits in cancer patients and 
increase the chance of survival. It was initially introduced as a definitive treatment or as an 
adjuvant therapy for asymptomatic patients with the aim to alleviate disease progress and 
improve survival. However, chemotherapy has an added benefit that it is able to act on locally 
confined tumours as well as metastasized malignancies, leading to increased benefits to later 
stages of the disease.  
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1.4.2 The Cell Cycle 
A cell undergoes a series of cycles, from the time it forms until it divides and matures; this is 
known as the cell cycle (91). A newly formed cell will undergo proliferation and then divide into 
two new cells, known as daughter cells. These daughter cells can then further proliferate and 
divide into mature differentiated cells (70). However only cells’ containing a nucleus 
(eukaryotes) are able to undergo the process of cell cycling (92). This is due to the fact that a 
duplication of the cell and its contents such as the organelles and DNA are made during the 
replication of the cell in the cell cycle.  
 
The events that occur during the cell cycle therefore are understood to correspond to the 
mitotic cycle (93). Most cells in the body are in a quiescent state, they will only undergo change 
by activating the cell cycle when there is a definite need. This need is triggered upon a proper 
mitogenic stimulus for example growth factors (94, 95).  The human cell cycle is accomplished 
in approximately 24 hours and classified into two stages: interphase and mitosis. Interphase 
is further classified into three major phases: G1 (gap 1), S (DNA Synthesis), and the G2 (gap 
2) phase, with mitosis being the M phase (96). Each of these phases has a very specific 
function that serves to ensure proper cell division resulting in a fully functional daughter cell. 
 
 
a) Interphase 
 
During interphase the cell grows and maintains its routine functions as well as its 
contributions to the internal environment. It is described as the phase when the cell 
accumulates material, nutrients and subsequently doubles its genome (92, 97). Interphase 
is divided into G1, S, and G2 phases based on the sequence of activities.   
 
b) Gap 1 phase 
 
The G1 phase is known as the gap between the end mitosis and the start of the S phase and 
is responsible for preparing the cell for DNA synthesis. In this phase the cell is sensitive to 
positive and negative cues from growth signalling networks (97, 98). However, while this 
phase may seem relatively uneventful, it is the most important regulatory phase in the cell 
cycle.  
 
The cell has the ability to decide to either irreversibly enter the cell cycle though mitosis or 
enter a quiescent phase. This decision making processes is controlled by occurrence known 
as restriction point (95). The restriction point occurs late in the G1 phase and once the 
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restriction point has been crossed, a strong commitment to proliferate has been triggered and 
a round of DNA replication is executed after the G1-S transition (94, 96). 
c) S phase
The S phase is the most important stage as this is where DNA synthesis occurs. The initiation 
of DNA synthesis occurs right at the G1/S phase transition. It is a delicate process whereby 
the cells genome is copied, producing an identical copy yielding a single cell with two sets of 
each chromosome (95, 96). Once this is completed the cell can enter the G2 phase before 
mitosis can occur. 
d) G2 (Gap 2) phase
The G2 phase the phase between the completion of the S phase and the beginning of mitosis. 
It is responsible for preparing the cell to enter the mitosis and serves as a buffer to ensure the 
DNA synthesis process is a complete phase (91). This phase functions in ensuring the 
required proteins for nuclear envelope breakdown, chromosome condensation, spindle 
formation, and other processes required for the cell to enter into mitosis is synthesises. DNA 
synthesis needs to be complete in order for mitosis-promoting functions to be initiated, 
therefore serving as a buffer phase to prevent premature cell division (96). Once this phase is 
complete the cell then has two sets of identical chromosomes, cell growth can then continue 
ensuring the cell doubles in size to allow for division in the mitosis phase. 
e) Mitosis
Mitosis consists of four sub stages, each with a specific action guaranteeing the complete 
separation of daughter chromosomes from the original cell, resulting in complete enclosure of 
the identical genetic material in the newly formed cells (92, 97).  This stage of the cell cycle is 
an essential step for the maintenance of genome stability (99).  
Prophase is the first sub stage, in which the nuclear envelope of the original cell is broken 
down by the protein synthesised in the G2 phase. The chromosomes are then condensed and 
spindle formation is initiated (99, 100). This is followed by Pro-metaphase being a transition 
period allowing the sister chromatids to shuffle around until they are aligned in the middle of 
the cell (96, 101). This alignment of the chromatids is termed Metaphase. The next sub stage 
Anaphase is responsible for separating the sister chromatids to opposite poles of the cell. 
Lastly, the physically division of the cell occurs resulting in the two separate daughter cells 
and is known as Telophase (95). 
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f) G0 phase
The G0 phase is known as the quiescent phase or resting phase. It is a state that enables the 
cells to function properly but not divide. Cells enter this stage when they have reversibly 
withdrawn from dividing in the cell cycle. This occurs due to mitogen deprivation or in response 
to a high cell density (95, 98). Most of the adult human cells are in this phase as they are 
already matured, unless activated by mitogenic stimulus such as tissue damage. However 
some tissues are constantly in the cell cycle process and this is due to their functionality, for 
example blood cells or skin cells that are in a constant state of maturation (101). This is 
strongly related to their on-going aging and limited life span (92). 
1.4.3 Types of Chemotherapeutic Agents 
As chemotherapeutic agents target cancer cells that are actively replicating, however there 
are different types, each with a different mode of action. Many act by directly damaging the 
cell’s DNA, interfering with cell division, leading to apoptosis (activated cell death) (102). 
Others act indirectly by interfering with the cell cycle (mitosis) or affecting the replication of 
cancer cells by blocking the use of nucleotides required for DNA synthesis (102, 103). These 
agents are classified based on their mode of action and chemical structure. There are three 
categories described, these being:  
1) Cell cycle phase–specific drugs, they are effective against cells that are active in a
particular phase of the cell cycle and target only that specific phase, for example during a
growth phase. These types of chemotherapeutic drugs are significant as they act on cancer
cells either in the G1 phase or S-G2-M phase of the cell cycle (102). As mentioned previously
these are the most crucial steps in the cell cycle and therefore lead to an increased cytotoxic
effect on the cancerous cells that are rapidly dividing or are in those specific stages on
proliferation. These types of drugs focus mainly on the vulnerability of the cancer cells and
thereby have the potential to enable clinical outcomes (104, 105). The only pitfall is that these
drugs reach a plateau with respect to their ability to kill cells and therefore an increase in drug
dosage will not cause an increase in cell kill once the plateau has been reached (106).
2) Cell cycle–specific drugs are effective against actively proliferating cells in a particular
phase, but do not require the cell to be in a specific phase of the cell cycle to be effective.
CDKs are certain proteins responsible for the activation of the cell cycle in cancer cells (103,
107). These proteins are found to be over-expressed whereas the cell cycle inhibitory proteins
are under-expressed; this leads to uncontrollable growth of cancer cells. The foundation
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behind the development of cell-cycle specific chemotherapeutic drugs is to target the over-
expressed proteins in cancer progression cells (105). This dynamical approach then causes 
an inducing inhibitory effect by blocking the cell cycle at the divisional phase. All cells in the 
cell cycle go through a resting phase and are considered to be in a quiescent state. The 
limitation seen in these types of chemotherapeutic drugs is that they do not affect cells in the 
resting stage of the cell cycle (103, 106, 107). Thereby these cells are thought of as being 
kinetically resistant to these types of chemotherapeutic drugs.  
3) Cell cycle–non-specific drugs are effective on cancer cells in any phase of the cell cycle, 
but mainly target cancer cells in the resting (G0) phase of the cell cycle. These 
chemotherapeutic drugs are active to any phase of the cell cycle. They have been found to be 
most effective against slow growing tumours as they mainly target quiescent cells. Their mode 
of action occurs as a bimolecular reaction and DNA is the target site for these types of drugs. 
Due to this fact maximum cell kill volume is not possible when cells are in the S phase of the 
cell cycle at the time the drugs are administered. These agents have a linear dose-response 
curve which allows for the greater the dose of drug administered, the greater the fraction of 
cells killed (106). The action of these drugs are therefore dependant on the drug concentration 
and the density of the cell (108).  
1.4.4 Classification of Chemotherapeutic Agents 
Chemotherapeutic agents are further classified into classes based on their action, structure 
and source. These classes being: Alkylating drugs, Antimetabolites and Natural products. 
Most alkylating drugs fall into the cell cycle–specific category and some are cell cycle–non-
specific as they cause DNA damage, enabling replication (102, 109). Antimetabolites act as a 
substitute for the metabolites that are used in normal metabolism; therefore, most fall into the 
cell cycle–specific category with some also being phase-specific. The last class being natural 
products such as antibiotics, mitotic inhibitors, Taxanes and topoisomerase inhibitors, they fall 
into the any of the three categories depending on the agent (109). As described, there are 
different types of chemotherapeutic agents all with their own unique actions for damaging 
cancer cells in different phases of the cell cycle and different ways. It is often difficult to 
determine the exact phase the cancer cells are at in differentiation, therefore to improve and 
increase the effectiveness of cancer cell killing a combination of these drugs are often 
employed (108, 109). This method of drug administration and treatment option is known as 
combination chemotherapy. 
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1.5 Chemoresistance 
1.5.1 Chemoresistance Defined 
Chemotherapy resistance is a phenomenon in human tumours that occur when tumour cells 
become tolerant to the effects of chemotherapeutic drugs and are mostly evident in advanced 
metastatic stages of the disease. This concept was first evident in bacterial states, when 
bacteria were found to become resistant to certain antibiotics (88, 110). Since then similar 
mechanisms had been found to occur in other diseases, including cancers. The primary cause 
of chemotherapeutic drug failure in most human tumours has been recognised to be due to 
drug resistance. Although other factors such as pharmacological factors including inadequate 
drug concentrations targeting the tumour site and cellular factors, contribute largely to clinical 
resistance of several tumour types (88, 89). The tendency of malignant cells to acquire 
mutations causes them to resist the effects of these therapeutic agents, therefore limiting the 
chemotherapy’s effectiveness leading to resistance. It has been found that heterogeneous 
tumours consisting of mixtures of chemo sensitive and chemo resistant cells initially respond 
to treatment. The patient then tends to relapse as the chemo sensitive cells undergo apoptosis 
and the chemo resistant cells remain, becoming predominant (102, 111).  
There are two types of distinct manifestations of chemotherapeutic drug resistance referred to 
as intrinsic (natural) or acquired resistance, illustrated in Figure 1.6 below. They are classified 
based on the initial response to the first exposure to the chemotherapeutic agent (89, 110, 
111). The intrinsic resistance occurs naturally prior to chemotherapy exposure and acquired 
resistance develops during treatment due to the sensitivity of tumours to the chemotherapy. 
In acquired resistance the tumour may become cross-resistant to a range of different 
chemotherapies depending on type and mode of action. However a common cellular base 
exists, both manifestations develop a simultaneous phenotypic resistance to a variety of 
structurally and functionally diverse agents (89). The drug resistance is a multifactorial 
phenomenon that involves multiple unified or independent mechanisms evident in both 
manifestations.  
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Figure 6: Types of chemotherapeutic drug resistance. An illustration of the two types of 
chemoresistance and the mechanisms of their occurrence due to chemotherapeutic drug exposure, 
with permission from (112). 
 
1.5.2 Factors Affecting Cancer Cell Sensitivity 
The concept of chemotherapy resistance is complex as numerous factors affect the sensitivity 
of cancer cells and are grouped based on their main mechanisms. These factors are grouped 
into three varieties: (1) decrease of active drug concentration at target level due to activation 
of transporter proteins or detoxification mechanisms within the cell; (2) alterations affecting 
drug–target interactions; (3) factors influencing the cellular response that affect tumour cell 
survival (89, 113). With regards to cellular response, the factor that has a major affect is the 
increased ability of the cell to repair DNA damage or tolerate stress conditions (111). It has 
been found that some methods of chemotherapy resistance are disease-specific, while others 
are evolutionarily conserved, such as drug efflux, observed in microbes and human drug-
resistant cancers (110, 113). Although many types of cancers are initially susceptible to 
chemotherapy, over time they can develop this chemotherapeutic drug resistance through 
these and other mechanisms, such as DNA mutations and metabolic changes that promote 
drug inhibition and degradation (110). Therapeutic failure is largely due to the heterogeneous 
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nature of most cancers which is a result of increased diversity of resistant phenotypes (111, 
113). Resistant cancer phenotypes become more aggressive over time and exposure to 
chemotherapeutic agents lead to poor clinical outcomes and decreased survival rates in 
patients.  
1.6 Aims & Objectives 
AIM:  
To identify the effects of chemotherapeutic drug exposure on the mechanical properties and 
cytoskeletal composition of drug sensitive and drug resistant malignant melanoma cells. This 
dissertation explores the hypothesis that exposure to a chemotherapeutic drug leads to a 
change in intracellular stiffness of malignant melanoma cells. Intracellular stiffness will be 
assessed by Actin and β-Tubulin as intracellular indicators.  
OBJECTIVES: 
Objective 1: To determine the mechanical properties and cytoskeletal composition of 
chemosensitive malignant melanoma cells (WM1158). This will be achieved via Passive 
based Multiple Particle Tracking Microrheology (MPTM) to capture the mechanical properties 
and Western Blotting and qRT-PCR techniques to examine the cytoskeletal composition using 
Actin and β-Tubulin. 
Objective 2: To investigate intracellular stiffness via MPTM, biochemical properties via 
Western blotting and mRNA via qRT-PCR of chemoresistant malignant melanoma cells (SK-
MEL 29). 
Objective 3: To identify intracellular stiffness and cytoskeletal composition changes of 
chemosensitive (WM1158) and chemoresistance (SK-MEL 29) malignant melanoma cells 
exposed to Cisplatin a chemotherapeutic drug. The data obtained will be compared to 
Objective 1 and 2 to achieve the aim of this study. 
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CHAPTER 2: Materials and Methods 
The following chapter describes the materials and methods for cell culture, multiple particle 
tracking microrheology (MPTM), molecular biology techniques and data analysis.  
2.1 Study Design 
This was a quantitative research, which utilised a combination of microrheology and molecular 
biology techniques to identify a linkage between chemoresistance and the cellular mechanics 
of cancer cells. A flow diagram demonstrating the study design is presented in Figure 7 while 
detailed descriptions of protocols used in this study is provided below. 
Figure 7: A flow diagram illustrating the study design of this research. 
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2.2 Cell Lines and Culture  
Two cell lines were used in this study. The WM1158 is a metastatic human derived melanoma 
cell line with mesenchymal morphology. This cell line was obtained by Prof S. Prince 
(Department of Human Biology, Prince Laboratory, University of Cape Town, SA). The cell 
line SK-MEL 29 is a human derived resistant metastatic melanoma cell line that was 
purchased from Memorial Sloan-Kettering Cancer Centre, New York, USA.  
Cell lines WM1158 and SK-MEL 29 were both cultured in RPMI 1640 medium (Highveld 
Biological, UK) pH 7.2, supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin 
and 100 μg/mL streptomycin. The cell lines were grown at 37°C in an air-humidified 
atmosphere containing 5% CO2 incubator and typically maintained in 10mm dishes in a 10mL 
volume of media. Cells were routinely passaged once a 80-90% confluence was reached with 
trypsin (Sigma-Aldrich, USA) centrifuged for 2min at (2000rpm) and re-suspended in fresh 
medium. Cells were initially subjected to mycoplasma tests and only mycoplasma free cells 
were utilised in experiments. 
Table 1: Cell culture media (RPMI 1640), antibiotics and supplements. 
Name of Product Quantity 
ddH2O 1 L 
NaHCO3 2.0 g 
RPMI powder 10.7 g 
FBS 50 mL 
Penicillin/Streptomycin (PenStrep) 5 mL 
 
 
2.3 Mycoplasma Test 
The mycoplasma test utilises the Hoechst stain which is a nuclei (DNA) staining solution and 
detects the presence of mycoplasma organisms within a cell culture. Cells were grown on a 
coverslip in a 35mm culture dish for minimum 24 hours in antibiotic-free medium (RPMI only).  
Coverslip containing cells were fixed with 1mL 1:3 mixture of glacial acetic acid and methanol 
(fixing solution) for 10sec x2, washed x3 gently with water to remove the fixing solution and 
air-dried at room temperature until dried (± 5min). Once dried, the DNA was stained with 0.5 
μg/ml Hoechst Stain (Sigma, St Louis, MO, USA) for 10 sec, briefly washed x3 with water to 
remove excess stain and then mounted on a slide with mounting fluid (see Appendix B). The 
cells were immediately viewed using a fluorescence microscope. Mycoplasma negative cells 
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stained positive with Hoechst stain only in the nucleus, while cells infected with mycoplasma 
showed staining in both the nucleus and the cytoplasm. 
Table 2: Hoechst stain mounting media. 
Name of Product Quantity 
0.1M citric acid 22.2 mL 
0.2M Na2HPO4.2H2O 27.8 mL 
Glycerol 50 mL 
Make up to 100mL, pH 5.5, store @ 4°C 
2.4 Seeding Densities 
The seeding densities for each experiment were determined by cell counting using a basic 
haemocytometer (Neubauer Chamber, Celeromics, Spain). Trypsinised cells were centrifuged 
at 2000rpms for 2min into a cell suspension. 10µL cell suspension was introduced between 
the glass coverslip and Neubauer chamber central area. A light microscope was used to 
perform the count, the four larger squares of the Neubauer chamber were counted and the 
average of the four areas was used to determine the concentration of seeding density. The 
concentration calculation formula as seen in Figure 8 below was used to determine the specific 
seeding density for both cell lines as indicated in each experiment. 
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Figure 8: Neubauer chamber and concentration calculation formula. An illustration of the 
Neubauer cell counting chamber as seen under a light microscope and the standardised cell 
concentration formula utilised for determining cell densities. 
 
2.5 Cisplatin Treatment 
Cisplatin (CDDP) is a palladium-based compound with potential anti-cancer activities. Based 
on these properties, Cisplatin was used as the treatment of choice for this study. Pre-prepared 
Cisplatin (Pfizer, South Africa) dissolved in dH2O to give a final concentration of 1mM was 
used for both WM1158 and SK-MEL-29 cell lines. A half maximum inhibitory concentration 
also known as IC50 value of (4.67µM) and IC50x2 value of (9.34µM) were used in all 
experiments and was made from the 1mM stock solution. Depending on the required volumes, 
the IC50 and IC50x2 treatment concentrations were established and both cell lines were 
treated at these specific concentrations for each experiment. Normal un-supplemented culture 
media only was used as the vehicle for all experiments as Cisplatin was dissolved in dH2O 
and normal culture media contained dH2O.  
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2.6 Cell Morphology  
WM1158 and SK-MEL 29 cells were plated at 5x104cells/mL and incubated for 24 hours in 
order to obtain 70-80% confluency on the day of treatment. Morphological changes were 
monitored by visual inspection and photographed using an inverted light microscope (Olympus 
1X71, USA) 4x objective and camera (Zeiss AxioCam, Germany) after CDDP treatment at 0 
hours, 24 hours and 48 hours, respectively.  
 
2.7 Microrheology 
2.7.1 Multiple Particle Tracking Microrheology 
Cells were plated in tissue culture glass-bottom well-plates used for high-resolution imaging 
and contain no additional substrate coating (Greiner Bio-One, Germany) (83, 114) at a seeding 
density of 10 x104cells/mL in RPMI 1640 no phenol red (Highveld Biological, UK) and 
incubated for 24 hours until 60% confluence. After 24 hours cells were treated with CDDP and 
incubated for a further 24 hours. Cells were then exposed to MitoTracker Green FM (Life 
Technologies, SA) and further incubated for 30min to allow the MitoTracker to diffuse through 
the cells. Two of the four wells of the culture dish were treated with CDDP; one was left 
untreated as a positive control and one with DMSO and no MitoTracker as the negative 
control. Through the course of the experiment cells were kept in an incubator and only 
removed for imaging sessions. Time lapse images were captured using a confocal microscope 
(Zeiss AxioCam, Germany) for a total of 90sec at 0.05fps (yielding a total of ±130 images per 
time lapse).  
These images captured the displacement of fluorescently labelled tracer particles 
(mitochondria) in the cytoplasm due to thermal fluctuations and were processed into time-
dependant x-y particle trajectories (87). The particle trajectories were used to quantify the 
amplitude of motions over different time scales by Brownian motion which is expressed as the 
Mean-Squared Displacement (MSD). This method is illustrated in Figure 9. 
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Figure 9: Microrheology of biomaterial hydrogelators. (A) Tracer particles are fluorescently 
labelled. (B) Sample medium with added tracer particles. (C) Video images presenting time-
dependant x-y particle trajectories. (D) Particle trajectories pathway are transformed into mean-
squared displacement (MSD) profiles and expressed graphically, with permission from (115). 
 
2.7.2 MDS and complex shear modulus calculations 
The captured image sequences from the confocal microscope were used to track the particles 
individually using MATLAB routines (The MathWorks, Natick, MA). These routines were 
originally written in IDL by Crocker (116) and ported to MATLAB by Blair (117). The MATLAB 
routines were utilised to i) locate particle positions for each frame, ii) filter unwanted tracks or 
particles that could be caused by digitization errors, table vibrations or noticeable intracellular 
motor transport motion), and iii) link the positions in each frame into tracks for a collection of 
frames. A MATLAB GUI that was written in-house using the particle tracking routines was 
used to obtain tracks from all the image sequences. Using the particle-ensemble averaged 
MSD at each lag-time the mechanical properties of cells were computed. The MSD and 
complex shear modulus were computed as described by others (77, 117, 118).  
 
The complex shear modulus (also known as the viscoelastic modulus) expresses the elastic 
modulus as the real (storage) component and the viscous modulus as the imaginary (loss) 
component. As suggested in previous findings and subsequently demonstrated in a number 
of studies the GSER was used for estimation of complex shear modulus from MPTM MSD 
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measurements in complex in live cells (69, 77, 79, 80, 90, 118). The mean of all squared 
displacements at a given time point for a minimum of 10 tracked particles was used per cell 
line condition to obtain the average MSD at each lag-time to determine the mechanical 
properties of the live cells in this experiment.  
 
2.8 Western Blot 
2.8.1 Cell harvest and lysate preparation 
Cells were harvested by trypsinisation and pelleted by centrifugation at 2000rpm for 2 minutes 
to remove medium and then washed with sterile 1xPBS. Harvested cells were then lysed by 
adding lysis buffer (1M Tris-HCL pH6.8, 10% SDS, glycerol, bromophenol blue, 
β-mercaptoethonol and dH2O), boiled for 10 minutes and then either used immediately or 
stored at -20°C prior to electrophoresis. 
 
2.8.2 Sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-PAGE) 
Under denaturing conditions proteins can be separated by their molecular weight in a sodium 
dodecyl sulphate polyacrylamide gel. Therefore, polyacrylamide gels consisting of a 12% 
separating gel (1.5M Tris-HCl (pH 8.8), 40% Acrylamide, 10% SDS, 10% APS, TEMED) and 
a 5% stacking gel (40% Acrylamide, 1.5M Tris-HCl (pH 6.8), 10% SDS, 10% APS, TEMED) 
were utilised for electrophoresis of protein samples. The polymerization reaction was initiated 
by adding ammonium persulphate (APS) and TEMED to the separating gel and poured 
immediately into gel casts. To ensure gels remained moist and air bubbles removed, 1% SDS 
was applied and the gels were left of set from 10-30min. Once set the 5% stacking gel was 
applied and left to set. Protein samples were loaded to the gels and gels were placed in a Mini 
Protean Tetra system (Bio-Rad, USA), submersed in running buffer and electrophoresed at 
100 volts until the blue dye present had reached the bottom of the gel. The sample proteins 
molecular weight was estimated by a protein standard designated “Prestained Protein Marker” 
was used for comparison. After electrophoresis, proteins were transferred onto nitrocellulose 
membrane for western blot analysis. 
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Table 3: Formulations for SDS-PAGE separating and stacking gels. 
Reagents Resolving gel 12% Stacking gel 5% 
H2O 8.6 mL 6.032 mL 
40% acrylamide 6 mL 800 µL 
1.5M Tris (pH 8.8) 5 mL - 
1.5M Tris (pH 6.8) - 1 mL 
10% SDS 200 µL 80 µL 
10% APS 200 µL 80 µL 
TEMED 20 µL 8 µL 
Total Vol. 20 mL 8 mL 
2.8.3 Western blot analysis 
Proteins were separated by SDS-PAGE and post electrophoresis gels were transferred onto 
a nitrocellulose (GE Healthcare, Life science, UK) membrane via a Turbo-blot transfer system 
(Bio-Rad, USA). Transfers were performed for 1 hour and 30 min at 100volts. Post transfer 
blots were stained with Ponceau S for 5 minutes, followed by 3 x washes with dH2O (until 
background became clear white). Post ponceau staining membranes were washed in 1x PBS-
T and blocked for 1 h with blocking buffer.  Membranes were then incubated with primary 
antibodies overnight at 4°C on shaker. Post primary antibody incubation membranes were 
washed 1 x 10 minutes and 2 x 5 minutes with 1X PBS-T followed by a 1 hour incubation at 
room temperature with the required horseradish peroxidase (HRP)-linked secondary antibody. 
Post-secondary antibody incubation, membranes were washed 1 x 10 minutes and 2 x 5 
minutes with 1X PBS-T followed by addition of enhanced chemiluminescence (ECL). Bound 
antibodies were detected by chemiluminescence by exposure to X-ray films. The expression 
of these proteins were quantified as the densitometry value analysed by ImageJ software and 
normalised to the appropriate loading control.  
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Table 4: Primary antibodies used in Western blot. 
Antigen Antibody MW Dilution Source 
Actin Mouse 42 kDa 1:4000 Abcam 
β-Tubulin Mouse 50 kDa 1:5000 Abcam 
p38 Rabbit 38 kDa 1:5000 Santa Cruz 
 
 
2.9 Quantitative Real Time PCR (qRT-PCR) 
2.9.1 RNA isolation 
To perform qRT-PCR, total RNA was isolated from cultured cells using the High Pure RNA 
Isolation Kit (Roche Diagnostics, Germany) according to manufacturer’s instructions. Cells 
were suspended in 200µL PBS and 400µL Lysis Buffer. The cell lysate was then transferred 
to a High Filter Tube, centrifuged for 15sec at 8,000 x g and the flow through was discarded. 
90µL DNase Incubator Buffer and 10µL DNase I mix was added and incubated for 15min at 
22°C. Next 500µL Wash Buffer I was added and centrifuged for 15sec at 8,000 x g. This step 
was repeated twice with 500µL Wash Buffer II. The filter tube was transferred to a clean sterile 
microcentrifuge tube, 50µL Elution Buffer added and centrifuged for 1min at 8,000 x g. 
 
2.9.2 Determination of nucleic acid concentration 
The concentration of nucleic acids (RNA) was determined spectrophotometrically using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, USA) by measuring 
absorbance at 260nm and blanked against DEPC water. Pure RNA was estimated by 
determining absorption ratio A260/A280 respectively and stored at -80°C. 
 
2.9.3 cDNA synthesis for RT-PCR 
The ImProm-IITM Reverse Transcription System synthesis kit from Promega Corporation 
(Madison, WI, USA) was used for cDNA synthesis preparation. Initially, the RNA sample was 
diluted to 5 ng/µL with RNase-free water based on the NanoDrop concentration. RNA sample 
was incubated for 5min at 70°C in Thermal Cycler PCR machine. According to manufacturer’s 
protocol, 10µL mixture Reverse Transcriptase Kit was added to the diluted RNA sample. The 
mixture contained 36.6 µL RNase-free water, 24 µL 5x Reaction Buffer, 14.4µL MgCl2, 6µL 
dNTP mix, 3 µL RNase, and 6 µL Reverse Transcriptase. The sample was briefly centrifuged 
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and loaded into the Thermal Cycler PCR machine, programmed as per Table 5: Settings for 
Thermal Cycler used for cDNA synthesis. and the resulting cDNA was stored at -20°C.  
Table 5: Settings for Thermal Cycler used for cDNA synthesis. 
PCR Step Temperature °C Time 
Step 1 25°C 5 min 
Step 2 42°C 1 hour 
Step 3 70°C 15 min 
Step 4 4°C 20 min 
 
2.9.4 Synthetic oligonucleotide primers for qRT-PCR 
The oligonucleotide primer sequences for all gene products used in qRT-PCR gene 
expression analysis are listed in table 2.4 below. The oligonucleotides were synthesized by 
QuantiTect® Primers (Qiagen, UK) and dissolved in 1xTE (Tris-EDTA Buffer) to make up the 
final concentration. 
Table 6: qRT-PCR Primers. 
Gene Product Source Catalog no. 
Human ACTC1 Qiagen QT00205296 
Human TUBB Qiagen QT00089775 
GUSB Qiagen QT00046046 
 
2.9.5 qRT-PCR 
Quantitative real time PCR (qRT-PCR) was performed to quantify the changes in gene 
expression of interest. Reverse transcription was performed as stated in section 2.2.4.3 above. 
qRT-PCR was conducted using capillaries on an Applied Biosystems StepOne Plus Light 
Cycler using SYBR Green master mix (Applied Biosystems, CA, USA). The master mix 
contained 2.6µL RNase-free water, 5 µL 2XKapa, 0.4 µL Primers and 1 µL BSA.  Briefly, 1µL 
of cDNA was combined with the 9µL Master Mix in the capillaries and run on the Light Cycler, 
programmed as per Table 7 below. Each DNA sample was quantified in duplicate and a 
negative control without cDNA template was run with every assay to assess the overall 
specificity. Melting curve analysis was carried out to ensure product specificity. The expression 
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levels were quantified using the comparative 2-ΔΔCT calculation method using GUSB as the 
housekeeping gene (119). 
 
Table 7: Programme for Light Cycler qRT-PCT machine.  
Steps Temperature °C Time Cycles 
Denaturation 95°C 3 min - 
 
 
PCR 
Step 1 95°C 10 sec 
40 Step 2 55°C 20 sec 
Step 3 72°C 1 sec 
Melting 65°C 15 min - 
Cooling 40°C 30 sec - 
 
 
2.10 Data and Statistical Analysis 
Raw data for MPTM was collected the confocal microscope and the images processed to 
obtain quantitative data using ImageJ Fiji. This quantitative data was processed into particle 
trajectories and further into MSD using Matlab.  
Raw data from the Western blot analyses was collected by scanning the photographic films 
and analysis using ImageJ. Antibody p38 was used for normalization of the data. This data 
was then statistically analysed. 
Raw data from the qRT-PCR method were used to determine the comparative threshold cycle 
(ΔΔCt)–based fold-change calculations. For these calculations, GUSB was used for 
normalization of the data. After normalization, the relative expression of each gene was 
determined for both cell lines (WM1158 and SK-MEL 29). Fold changes in gene expression 
were expressed as the difference in expression of treated vs untreated cells for both cell lines.  
Statistical significance was determined with the student t test for p values less than 0.05. For 
multiple comparisons, p values were adjusted using Bonferoni correction.  Statistical analysis 
performed using Microsoft Excel and SPSS software version 6.02. 
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CHAPTER 3: Results 
 
The aim of this study was to identify the effects of chemotherapeutic drug exposure on the 
mechanical properties and cytoskeletal composition of drug sensitive and drug resistant 
malignant melanoma cells. A morphology study was initially performed to determine the 
cytotoxicity of cisplatin and confirm the resistance to the chemotherapeutic drug of the 
chemoresistant cell line. Multiple particle tracking microrheology (MPTM) was performed to 
determine the mechanical properties of the cancer cells. Western blot was performed to 
confirm the presence of the protein product and qRT-PCR was performed for the quantification 
of gene product of interest.    
 
3.1 Morphology study to assess cytotoxic effect and confirm chemoresistance 
Morphology changes between non-treated and treated cells with cisplatin were used to screen 
for cytotoxic effects of the cisplatin on WM1158 in conjunction with confirming 
chemoresistance in the SK-MEL 29 malignant melanoma cell line. The cells were treated with 
a compound concentration that inhibits cell growth by 50% (IC50) for 48 hours. A comparison 
between WM1158 and SK-MEL 29 cell lines were made by imaging the cells at 0 hours, 24 
hours and 48 hours, to determine the effect of the chemotherapeutic treatment over time and 
presence of chemoresistance.   
In Figure 10a and b it is evident that at 0 hours cells are replicating, as mitosis is occurring 
expressed by the white halo surrounding the cells. Comparing the 24 hours post treatment 
time point (Figure 10c) expresses the rounds of cells with no mitosis and (Figure 10d) reveals 
that cells maintained morphological structure and presences of mitosis. The 48 hour post 
treatment time point revealed (Figure 10e) complete rounding of cells as an indication of 
apoptosis compared to (Figure 10f) expressing normal morphological patterns and presence 
of mitosis still present.  
35 
Figure 10: Cisplatin cytotoxic effects on WM1158 and presence of chemoresistance in SK-MEL 
29. Representative phase-contrast photomicrographs (400x; Olympus 1X71) showing WM1158 and
SK-MEL 29 cells treated with Cisplatin at 0 hours (a, b), Cisplatin treatment at 24 hours (c, d), and
Cisplatin treatment at 48 hours (e, f), inserted arrows (a, b) indicating white halo of cells undergoing
mitosis.
3.2 Cell mechanical properties obtained by multiple particle tracking 
microrheology 
Multiple particle tracking microrheology (MPTM) was performed to probe the mechanical 
properties of individual living cells and the MSD of MitoTracker-stained mitochondria 
embedded in the cells was then calculated. The MSD provides information concerning the 
motion of particles in cytoplasm and indirectly about the cell microenvironment mechanics.  
The MSD of non-chemoresistant malignant melanoma cell line WM1158 was compared to the 
chemoresistant malignant melanoma cell line SK-MEL29. Both cell lines were then treated 
with cisplatin for 24 hours and then exposed to the MitoTracker prior to MPT as mentioned in 
objective 3.  
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3.2.1 Non-resistant Cancer Cells without Treatment 
MPTM was used as it determines the mechanical properties of WM1158 cancer cells, i.e. 
locally measures the viscoelastic properties of the cytoplasm. Cells were cultured and exposed 
to MitoTracker 30 min before microscopy. Under a 60X (oil immersion) objective lens on the 
confocal microscope, the fluorescent MitoTracker-stained mitochondria were visible inside the 
cells, which was explained in detail in section 2.2.6.1. The mechanical properties of WM1158 
malignant melanoma cells were determined by capturing a time series images of single cells 
at 0.05fps for the duration of 90sec.  
Figure 11a shows an example of overlay image of a single cell exposed to MitoTracker during 
the monitoring process of the time series. Figure 11b shows the example of particle trajectories 
expressing Brownian motion of the cell in Figure 11a.  
 
Figure 11: Particle Trajectories of WM1158 cancer cells. a) Fluorescence micrograph used for the 
identification and tracking of particles within the cell, with scale bar representing 20 µm. b) Visualisation 
of imported trajectories expressing Brownian motion. 
 
3.2.2 Chemoresistant cancer cells without treatment 
The mechanical properties of SK-MEL29 chemoresistant malignant melanoma cells were 
determined by capturing a time series images of single cells at 0.05 frames per second (fps) 
for the duration of 90sec.  
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Figure 12a shows an example of overlay image of a single cell exposed to MitoTracker during 
the monitoring process of the time series. The cell displayed extensive expression of 
MitoTracker which was distributed relatively heterogeneously throughout the cell as detected 
by fluorescent microscopy. Figure 12b shows the example of particle trajectories expressing 
Brownian motion of the cell in Figure 12a.  
 
Figure 12: Particle Trajectories of SK-MEL29 cancer cells. a) Fluorescence micrograph used for the 
identification and tracking of particles within the cell, with scale bar representing 20 µm. b) Visualisation 
of imported trajectories expressing Brownian motion. 
 
3.2.3 Non-resistant and chemoresistant cancer cells exposed to chemotherapeutic 
drugs 
Both WM1158 and SK-MEL29 cell lines were treated with cisplatin 24 hours before exposure 
to the MitoTracker. Figure 13 shows the effects of cisplatin on the cells exposed to the 
MitoTracker and DMSO as a positive result for both WM1158 and SK-MEL29 as a comparison.  
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Figure 13: Cisplatin treated cells exposed to mitotracker for determination of mechanical 
properties of cancer cells.  Representative confocal photomicrographs showing WM1158 and SK-
MEL 29 cells with positive controls with mitotracker and no treatment (a, b), and Cisplatin treated with 
concentration IC50 and mitotracker (c, d). Images were captured under a confocal microscope (Zeiss, 
Germany) at 600x magnification and are representative of a randomly selected field for each condition 
(scale bars indicate 20μm). 
 
As seen in Figure 13c the cisplatin and MitoTracker combined was too harsh for WM1158 cell 
line and caused all cells to undergo apoptosis. This experiment was repeated 3x times, 
producing the same results in all instances. The mechanical property expression could 
therefore only be determined on SK-MEL29 chemoresistant malignant melanoma cell line. 
Figure 14a shows an example of an overlay image of a single cell exposed to cisplatin and 
MitoTracker during the monitoring process of the time series. The cell displayed extensive 
expression of MitoTracker which was distributed relatively heterogeneously throughout the 
cell as detected by fluorescent microscopy. Figure 14b shows the example of particle 
trajectories expressing Brownian motion of the cell in Figure 14a.  
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Figure 14: Particle Trajectories of SK-MEL29 cancer cells exposed to cisplatin. A) Fluorescence 
micrograph used for the identification and tracking of particles within the cell, with scale bar representing 
20 µm. B) Visualisation of imported trajectories expressing Brownian motion. 
 
3.2.4 Cancer cell mechanics presented as MSD values  
After imaging, the particles were tracked in the time laps images using MATLAB tracking 
software as described in section 2.2.6.2 and the MSD was computed. Figure 15 shows the 
graph of ensemble MSD vs lag time in for WM1158 cells and SK-MEL29 cells studied in this 
experiment. The graph illustrates that the slope of MSD vs 𝜏𝜏 is 0 < α < 1, indicating a sub-
diffusion dynamic behaviour for the motions of the intracellular particles in the studied cancer 
cell lines over time intervals.  
 
Figure 15: Cancer cell mechanics presented as MSD over lag time. A diagram of the ensemble 
averaged MSD vs lag time for cell lines WM1158, SK-MEL29, and SK-MEL29 IC50 exposed to cisplatin.  
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Figure 16: Power Law coefficient 𝛼𝛼 obtained from MSD values. A diagram portraying the α values 
of both WM1158 and SK-MEL29 cell lines under the two conditions of Mitotracker exposure only and 
Mitotracker combined with cisplatin treatment. The MSDs of particle trajectories from the Mitotracker 
anchored to the mitochondria within cancer cells which exhibits anomalous diffusion dynamics as 
presented in equation 2 from section 1.3.3.2, 〈∆𝑟𝑟2(𝑡𝑡)〉 ~𝑡𝑡𝛼𝛼 (subdiffusive 𝛼𝛼 <1 and superdiffusive 𝛼𝛼 >1).  
As shown in Figure 16, the WM1158 cell line exhibited a super-diffusive pattern with mean 
α=1.99 for a lag time of up to 4 s. The SK-MEL29 chemoresistant malignant melanoma cell 
line presented a pure diffusion dynamic behaviour with mean α=0.86, i.e. ≈ 1 for the motions 
of the intracellular particles throughout time intervals. Lastly, the SK-MEL29 IC50 condition 
revealed sub-diffusion dynamic behaviour (mean α=1.46) for the motions of the intracellular 
particles at short time intervals. 
3.3 Molecular adaption of the cytoskeletal properties of malignant melanoma 
cells assessed by Western Blot 
3.3.1 Actin protein expression 
The protein expression of actin was determined in both cell lines by SDS-Page and 
immunodetection. Briefly, cell lysates were prepared from 70-80% confluent cells and loaded 
onto polyacrylamide gels as described in section 2.2.3. Actin was resolved on precast 
SDS12% gels. Following electrophoresis, proteins were electrotransferred onto nitrocellulose 
and probed for target protein using specific antibody (Table 4). A monoclonal antibody 
commercialised by Life Technologies was utilised, with p38 as a loading control. The predicted 
molecular weight of actin is 42kDa (Figure 17). 
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Figure 17: Actin protein analysis. A) Western Blotting of cell extracts from WM1158 and SK-MEL29 
visualising actin protein indicated at approximately 42 kDa and normalised to corresponding p38 
signals. The conditions for this experiment represent positive (+) as no treatment, IC50 as half the 
inhibitory concentration dose of cisplatin and 2xIC50 as twice the inhibitory concentration dose of 
cisplatin. Image J image analysis software was used to quantify signal intensities; these signal 
intensities are shown in the table below the western blot. B) Successful transfer of proteins onto the 
membrane and visualized by ponceau stain, serving as normalization for protein loading.  
 
It is evident that there is a decrease in actin protein in the treated conditions, i.e. IC50 and 
2xIC50, compared to the non-treated condition of the WM1158 cell line. In contrast to the non-
resistant WM1158 cell line, the chemoresistant SK-MEL29 cell line exhibited increased actin 
levels for treatment conditions compared to the non-treated condition. Quantification of protein 
expression is shown in Figure 18.  
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Figure 18: Quantification of Actin protein expression. Histogram representing the expressing of 
relative actin protein concentrations (fold change) throughout the various experimental conditions 
obtained from Western blot quantification via ImageJ.  The conditions for this experiment represent 
positive (+) as no treatment, IC50 as half the inhibitory concentration dose of cisplatin and 2xIC50 as 
twice the inhibitory concentration dose of cisplatin, with error bars representing the STDEV.  
Asterisks indicated statistical significance of treated conditions compared to the non-treated control of 
the same cell line. 
 
 
3.3.2 β-Tubulin protein expression 
The protein expression of β-Tubulin was determined in both cell lines by SDS-Page and 
immunodetection. Briefly, cell lysates were prepared from 70-80% confluent cells and loaded 
onto polyacrylamide gels as described in section 2.3.3. β-Tubulin was resolved on precast 
SDS12% gels. Following electrophoresis, proteins were electrotransferred onto nitrocellulose 
and probed for target protein using specific antibody (Table 4). A monoclonal antibody 
commercialised by Life Technologies was utilised, with p38 as a loading control. The predicted 
molecular weight of β-Tubulin is 50kDa (Figure 19).  
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Figure 19: β-Tubulin protein analysis. a) Western Blotting of cell extracts from WM1158 and SK-
MEL29 visualising actin protein indicated at approximately 50 kDa and normalised to corresponding 
p38 signals. The conditions for this experiment represent positive (+) as no treatment, IC50 as half the 
inhibitory concentration dose of cisplatin and 2xIC50 as twice the inhibitory concentration dose of 
cisplatin. Image J image analysis software was used to quantify signal intensities; these signal 
intensities are shown in the table below the western blot. b) Successful transfer of proteins onto the 
membrane and visualized by ponceau stain, serving as normalization for protein loading.  
 
With regards to β-Tubulin it is evident that there is a similar protein expression pattern as seen 
in actin protein expression. For the WM1158 cell line, β-tubulin decreases in IC50 and IC50x2 
treatment conditions compared to non-treated control. The chemoresistant SK-MEL29 cell line 
shows, however, an increase in protein expression for IC50 treatment condition and no change 
for the IC50x2 treatment compared to the non-treated control. Quantification of protein 
expression is shown in Figure 20.  
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Figure 20: Quantification of β-Tubulin protein expression. Histogram representing the expression 
of relative β-Tubulin protein concentrations throughout the various experimental conditions obtained 
from western blot quantification via ImageJ. The conditions for this experiment represent positive (+) as 
no treatment, IC50 as half the inhibitory concentration dose of cisplatin and 2xIC50 as twice the 
inhibitory concentration dose of cisplatin, with error bars representing the STDEV. 
 
3.4 Gene expression of cytoskeletal properties of malignant melanoma cells 
assessed by qRT-PCR method 
3.4.1 Actin mRNA expression 
After confirming a decreased expression of actin protein in WM1158 treated cells, mRNA 
expression was determined by qRT-PCR as described in section 2.2.4. Relative expression 
were calculated for both cell lines and compared to their respective control cell lines. The 
mRNA expression of housekeeping gene GUSB (primer details in Table 6) was used to 
standardise the samples. The relative expression of ACTC1 mRNA was calculated as the ratio 
between the expression of ACTC1 gene and the expression of the housekeeping gene, with 
a negative control included in each experiment.  
Figure 21 shows the data from this experiment, which demonstrated low mRNA expression of 
the ACTC1 in WM1158 cells compared to SK-MEL29 (relative mean expression = 4.18, 
p<0.005).  
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Figure 21: qRT-PCR estimated mRNA concentration. Bar graph illustrating the relative normalised 
mRNA concentration for WM1158 and SK-MEL 9 cell lines. Primers specific to actin (ACTC1) was used 
and in both indicated cell lines, mRNA levels were first normalised to GUSB and then expressed relative 
to actin. The conditions for this experiment represent positive (+) as DMSO only no cisplatin treatment, 
IC50 as half the inhibitory concentration dose of cisplatin and 2xIC50 as twice the inhibitory 
concentration dose of cisplatin, with error bars representing the STDEV. 
3.4.2 β-Tubulin mRNA expression 
After confirming a decreased expression of β-Tubulin protein in WM1158 treated cells, mRNA 
expression was determined by qRT-PCR as described in section 2.2.4. Relative expression 
was calculated for both cell lines and compared to their respective control cell lines. The 
mRNA expression of housekeeping gene GUSB (primer details in Table 6) was used to 
standardise the samples. The relative expression of TUBB mRNA was calculated as the ratio 
between the expression of TUBB gene and the expression of the housekeeping gene, with a 
negative control included in each experiment.  
Figure 22A shows the data from this experiment, which demonstrated a decreased mRNA 
expression of the TUBB in WM1158 treated cells compared the untreated WM1158 cells and 
SK-MEL29 cells (relative mean expression = 0.79, p<0.66).  
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Figure 22: qRT-PCR estimated mRNA concentrations. Bar graph illustrating the relative normalised 
mRNA concentration for WM1158 and SK-MEL 9 cell lines. Primers specific to β-Tubulin (TUBB) was 
used and in both indicated cell lines, mRNA levels were first normalised to GUSB and then expressed 
relative to β-Tubulin. The conditions for this experiment represent positive (+) as DMSO only no cisplatin 
treatment, IC50 as half the inhibitory concentration dose of cisplatin and 2xIC50 as twice the inhibitory 
concentration dose of cisplatin, with error bars representing the STDEV. 
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CHAPTER 4: Discussion 
 
Cancer patients treated with chemotherapeutic agents usually show a promising initial 
response, however patients that relapse ultimately succumb to their disease due to the 
development of resistance (120). Regulation of cellular drug uptake, increased DNA damage 
repair, and inhibition of apoptosis have been proposed to cause chemoresistance (121). The 
development of strategies for chemosensitization and prevention of therapeutic resistance 
remains a major goal with important clinical implications.  
Cellular mechanical properties serve as a powerful label-free marker that could be used to 
gain insight into changes on a molecular scale within the cell. It is also useful in characterising 
different cellular stages and states for the use of potential diagnostic information. Most cancer 
forms have a long latency period causing the diagnosis to only take place at late stages of the 
disease; at this stage unfortunately resistance to chemotherapy is already present. For these 
reasons mentioned and the fact that chemoresistance is not easily detectable, identification of 
new and specific biomarkers is critical in guaranteeing early detection and defining treatments 
that would be more efficient (122-124). This is evident that during cancer progression a cell 
progresses from a full mature post mitotic state cell to a motile proliferative cancerous state. 
During this process, dramatic reorganisation of the actin cytoskeleton occurs that lead to a 
deviation from the original mechanical properties of the cell (125, 126). 
 In this study, the mechanical properties or non-resistant and chemoresistant cancer cells were 
studied in malignant melanoma cells to determine the mechanistic basis for chemoresistance. 
These cells were chosen based on their aggressive nature. Malignant melanoma is an 
aggressive skin cancer with its incidence rate worldwide increasing faster than any other 
known cancer type (127). The survival rate is presently less than 10% and patients having a 
10-year survival rate upon being diagnosed with metastatic melanoma (128). However surgery 
being a successful treatment for primary melanomas, treatment options for metastatic 
melanoma remains to be a change and is mainly treated with chemotherapeutic drugs. 
Metastatic melanoma however is reported to be the most resistant to chemotherapeutic drugs 
of all human cancers and based on this fact has been chosen as cells of choice for this study 
(129).  
As noted in chapter 1, the organisation of specific cytoskeletal elements such as actin and 
tubulin can reflect the diverse mechanical properties of the cells of interest. To date, there has 
been little characterisation of  these two major cytoskeletal elements composition (130, 131) 
and none that directly compared the cytoskeletal composition of malignant melanoma and 
chemoresistance. Therefore, in this study we have utilised a combination of scanning laser 
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confocal microscopy coupled with the multiple particle tracking microrheology, quantitative 
RT-PCR and Western blotting to analyse the organisation of and quantify actin and β-tubulin 
in malignant melanoma and resistant malignant melanoma cell lines.  
 
4.1 Morphological Examination 
The overall morphological appearance was studied to determine the cytotoxic effect of 
cisplatin on non-resistant malignant melanoma cells WM1158 and to confirm the resistance of 
chemoresistant malignant melanoma SK-MEL29 cells. WM1158 and SK-MEL29 cells were 
exposed to an IC50 concentration of cisplatin for 48 hours. The cells’ morphology was 
observed at three time points (0 hours, 24 hours and 48 hours). Distinct differences in cellular 
morphology were observed by bright field light microscopy (Figure 10) between the metastatic 
melanoma cell line WM1158 and the resistant metastatic melanoma cell line SK-MEL29.  
Compared to 0 hour exposure, cisplatin displayed a potent cytotoxic activity in the WM1158 
cells at 48 hours. Cell line SK-MEL29 however displayed no change to the cisplatin exposure 
and continued proliferation.  At 24 hours, cell line WM1158 displayed an epithelial cell like 
shape while the resistant SK-MEL29 cells displayed spindle-shape morphology in response 
to the cisplatin treatment. Based on these results it is evident that the cisplatin utilised in this 
study had strong cytotoxicity levels and that SK-MEL29 was indeed chemoresistant.  
 
4.2 Multiple Particle Tracking Microrheology 
In this study, a new functional microscopy technique, MPTM, has been employed which allows 
the local micromechanics of living cells to be probed. This technique allows for the 
measurement of averaged cell parameters to be compared to parameters obtained from more 
classical approaches and allows spatial variations of intracellular mechanics to be revealed. 
Previous works have made use of classical approaches by either studying mechanical 
properties without the control of cell geometry thereby on focusing on large cell-to-cell viability 
(80, 132, 133) or by using a more conventional approach of atomic force microscopy or 
magnetic twisting cytometry that measures the cells surface regional rigidity variations (134-
136).   
Central to this approach is the statistical analysis of the MSD of particle trajectory distributions 
throughout the cells’ cytoplasm making use of Brownian motion and the power law. In this 
study we evaluated the mechanical properties of malignant melanoma WM1158 and 
chemoresistant malignant melanoma SK-MEL29 cells, measuring MSDs of tracked particles 
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attached to the intracellular mitochondria using MPTM. Previous work have found that MSD 
amplitude is shown to be inversely related to intracellular stiffness (137), based on this 
principle the MPTM experiment was performed.   
The time-lapse imaging of the mitochondria in the cytoplasm allowed for direct mapping of the 
displacement field of the malignant cell’s cytoplastic environment, which can be seen in Figure 
11, Figure 12 and Figure 14, respectively. From these images the particle trajectories were 
presented expressing Brownian motion. Microrheology measures this Brownian motion and 
relates this motion into rheological properties, such as viscosity, using the generalised Stoke-
Einstein relation (GSER) as described in section 1.3.3.2. According to the power law exponent 
(𝛼𝛼) (equation 2) is a representative of the type of motion the particle undergoes. This state of 
the particles within the cell of interest can be determined using the logarithmic slope of MSD 
which is determined at the shortest lag times measured by MPTM. The shortest lag times are 
the largest frequencies measured and thereby capture the longest relaxation times of the 
particles. With regards to cisplatin treated WM1158 cells it had been found that the treatment 
in combination with the MitoTracker was an extreme harsh environment and causing cells to 
undergo apoptosis as seen Figure 13.  
The individual mitochondrial MSDs of each cell has great variability in the distribution of the 
slope, this is due to individual cells being extremely heterogeneous and so each particle will 
express a different MSD depending on its location within the cell. Based on this principle, the 
ensemble average MSDs obtained from all cells of each cell line and experimental condition 
were plotted. As shown in Figure 15, the ensemble average of MSD of WM1158 cells clearly 
shows an increase in the slope of the MSD curve with an increased lag time indicating a super-
diffusive motion behaviour at particular time intervals associated with a loss of stiffness and 
decrease in elastic nature of the cells. A similar trend was observed in SK-MEL29 exposed to 
treatment shown in Figure 16. For the chemoresistance cell line SK-MEL 29 with no treatment, 
the ensemble averaged MSDs show an increase in amplitude with 𝛼𝛼 = 1 representing a pure 
diffusion of fluid-like motion (Figure 16).  
This MPTM study revealed changes in the internal mechanism and activity of cells exposed 
to chemotherapeutic agents and cells undergoing transformation. The results from this study 
showed that MSDs in SK-MEL29 cells without drug exposure were significantly higher than 
those in WM1158 and SK-MEL29 treated cells; this is due to cells being less dense and 
possessing a more active cytoskeletal network. These results suggest that tumorigenicity of 
cells largely correlated with an increase in intracellular activity and a decrease in cell stiffness 
and structural density. Based on these results and measurement of mechanics over time, it is 
also suggested that apoptosis causes cells to become more viscous and elastic over time. 
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From the findings from the MPTM experiment, we propose that, in the case of malignant 
tumours, cellular stiffness was drastically reduced i.e. cells were softer nature in non-resistant 
malignant cell line than the chemoresistant cell line. Comparing non-resistant cells to 
chemoresistance cells, the resistant SK-MEL29 cells proved to have less elasticity and be 
stiffer in nature.  
4.3 Western blot analysis 
A protein expression study was conducted by means of Western blotting. Sample blots were 
analysed quantitatively, normalised to p38 and compared to untreated cells which also 
functioned as a control for statistical difference determination. Protein levels of actin and β-
tubulin were quantified and altered expression levels of both cytoskeletal elements were found 
comparing WM1158 to resistant SK-MEL29 cell line (Figure 17a & Figure 19a, respectively). 
The results highlighted the presence of actin at approximate 42 kDa and β-tubulin at 
approximately 50 kDa that matches the predicted size as per antibody datasheet.  
Actin is found to be the most abundant protein in eukaryotic cells. Due to its highly conserved 
nature it participates in more protein-protein interactions than any other known protein. Actin 
also has the ability to transition between monomeric (G-actin) and filamentous (F-actin) states 
under the control of ions, nucleotide hydrolysis and a number of actin-binding proteins (138). 
These transitional abilities along with the mentioned properties make actin a critical part in 
many cellular functions. These functions range from cell motility to the maintenance of cell 
shape and polarity of transcription regulation. Based on this, the expression of actin was used 
to evaluate the protein expression in cancer cells and chemoresistant cells in conjunction with 
mechanical evaluations. The expression of actin protein levels in WM1158 cells revealed a 
significant down regulation in treated cells compared to untreated (control) cells. Nevertheless, 
SK-MEL29 cells presented with an up-regulated protein expression when comparing treated 
to untreated (control) cells (Figure 18).  
β-Tubulin is a heterodimer found in the dynamic intracellular structure known as the 
microtubule cytoskeleton. The microtubule cytoskeleton plays a critical role in supporting 
cellular structure; transporting vesicles, proteins, and organelles; and enabling cell motility.  
Due to the nature of β-Tubulin and its important role in the cytoskeleton of cells it was used to 
evaluate the protein expression in cancer cells and chemoresistant cells in conjunction with 
mechanical evaluations. With regards to β-tubulin, a similar pattern as for actin protein can be 
seen in both WM1158 and SK-MEL29 cell lines for both treated and untreated conditions 
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(Figure 20). These results indicated that cisplatin produced a difference in the amount of 
protein expression in the treated cells compared to the control.  
Studies have found that platinum compounds such as cisplatin are able to bind to cellular 
proteins of the cytoskeleton such as actin and tubulin (139, 140). Consistent with this, the 
current study revealed that cisplatin treatment of the non-resistant WM1158 cell line clearly 
affects the cytoskeleton by causing morphological changes as well as distinct changes in the 
protein expression of actin and β-tubulin. Cytoskeletal changes observed for treatment of 
chemoresistant cells were not statistically significant, and the slight up regulation of protein 
levels is ascribed largely to the continuous differentiation of malignant tumour progression.  
 
4.4 qRT-PCR analysis 
Quantitative RT-CPR was conducted to analyse the mRNA expression for both actin and β-
tubulin to determine if any inherent gene differences were present leading to cytoskeletal 
element changes in the presence and absence of cisplatin. The mRNA expression of actin 
(ACTC1) and β-tubulin (TUBB) for both WM1158 and SK-MEL29 cells were normalised to 
GUSB a housekeeping gene and compared to untreated cells which also functioned as a 
control for statistical difference determination.  
In addition to the effects of cisplatin presented at the protein level, we demonstrated a 
differential gene regulation at the mRNA level. The relative actin mRNA levels were affected 
in a similar manner to the protein expression in WM1158 and SK-MEL29 cells (Figure 21), 
suggesting that cisplatin’s point of interference was the DNA sequence. However, β-tubulin 
mRNA and protein expression was influenced differently by cisplatin treatment, with a 
decrease in protein expression (as mentioned in section 4.3), but an increase in mRNA 
expression (Figure 22). This pattern had been found in previous studies and suggests that 
cisplatin may influence certain genes differently at the post-transcriptional or post-translational 
levels without affecting the DNA sequence, which could be linked to epigenetic regulation 
(141, 142). 
It has been found that at IC50 dose of cisplatin, the chemotherapeutic drug kills tumour cells 
by interfering with the cellular structure and function at the DNA level, which is also evident in 
this study.  At the same time as cellular structure and DNA function are affected, cisplatin 
appeared to regulate gene expression, and therefore to interfere with the stage of cellular 
differentiation, both at the mRNA and protein levels. This is in agreement with previous studies 
showing that some tumour cells require high doses of chemotherapeutic agents to undergo 
complete apoptosis (143-145). Low, non-toxic dosage may however have a different effect on 
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the cells without causing cell death. This differential response suggests that cisplatin may act 
in tumour-specific manner, depending on the properties and cellular hierarchy manifested by 
each tumour. Based on these findings it has been found that development of chemoresistance 
depends largely on the type of tumour, its progression and dosage and exposure time of the 
chemotherapeutic drug.  
 
4.5 Overall Findings 
Using a combination of Multiple Particle Tracking Microrheology, quantitative RT-PCR and 
Western blotting, we have demonstrated that actin and β-tubulin have altered architectures as 
well as differences in protein and gene levels in malignant melanoma cells and chemoresistant 
malignant melanoma cells. We have applied intracellular MPTM in live cells to study the 
mechanical properties of malignant cancer cells and cancer cells exposed to 
chemotherapeutic drugs. Using MPTM we were able to detect and provide quantitative 
estimates of cellular mechanical property changes that occurred in each condition. It was 
shown that cell stiffness decreases as the cancer cells’ metastatic potential increases; thereby 
as cancer progresses the cells become stiffer. This pattern was evident for chemoresistant 
malignant cells as well and revealed that they had a loss of elasticity in comparison to their 
counter non-resistant malignant cells. With regards to protein levels and mRNA expression, 
cisplatin affected the cytoskeleton causing cells to undergo morphological changes which, 
however, was not seen in chemoresistant cells. These findings suggest in particular that 
chemoresistance development depends largely on the type of cancer and its stage of 
progression and also the chemotherapeutic agent dosage and exposure times. 
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CHAPTER 5: Conclusion 
 
This study is one of the first investigations that makes use of a combination of bioengineering 
and molecular approaches to compare the response of drug-sensitive and drug-resistant 
malignant melanoma cells to chemotherapeutic drug exposure. The findings from this study 
and MPTM experiments identified biophysical cell parameters for the screening of cancer and 
its progression. We hypothesised that exposure to a chemotherapeutic drug leads to a change 
in intracellular stiffness of malignant melanoma cells and found that malignant chemoresistant 
cells are indeed stiffer in nature. In particular, this study revealed that single cell mechanical 
phenotyping appears to be a quick and efficient marker and additional support in cancer 
diagnosis providing a deeper understanding of cancer mechanobiology and in the definition of 
new diagnostic tools for chemoresistance in cancer therapies. 
 
5.1 Future Research 
MPTM has been found to be a useful tool in studying the mechanical properties of live cells. 
In this work, by staining, the mitochondria were used as tracker particles that enter the cells 
by endocytosis and attached to the mitochondria within the cytoplasm. A limitation 
experienced in this study was the harsh apoptotic effects that the Mitotracker combined with 
cisplatin treatment had on the non-resistant cell line. This could largely be due to the means 
by which the Mitotracker enters the cells and the incubation time of exposure before viewing 
using confocal microscopy. Future studies could possibly address this issue by either 
exploring different incubation times of Mitotracker exposure with different dilution 
concentrations. The Mitotracker dilution concentration could be adjusted in combination with 
different exposure times to determine the optimal concentration of Mitotracker combined with 
chemotherapeutic drug. By finding an optimal dilution concentration it may be possible to limit 
the cytotoxicity of the Mitotracker combined with cisplatin and allow the cell wall to undergo 
some form of repair with a longer incubation period. However, it should be noted that the aim 
of cisplatin is indeed to cause cells to undergo apoptosis and thereby provides limited 
incubation time before cytotoxicity levels are reached.  
There are however other methods for the insertion of particle tracers into cells. An interesting 
aspect could be to compare the results obtained from various methods, such as microinjection 
and ballistic injection. Using these methods might allow a less harsh environment for treated 
non-resistance cells allowing the full scope of the study. The ballistic method is interesting in 
particular that it allows for much larger tracking environment with less damage to cells with 
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respect to the microinjection (146). By using different types of particles and injection methods 
a more complete picture of the cell’s mechanical properties can be obtained. These methods 
would also allow for the measurement of how the cellular properties change in different 
locations within the cell such as the nucleus compared to the cytoplasm. This will develop a 
mechanical map that will part of the cell is predominantly responsible for the chemoresistance 
development. A mechanical mapping of a cell could be developed at different time points for 
both treated and un-treated cells. This would however require a mathematical tool such as the 
tools developed for non-biological materials to be developed (147).These methods propose 
an advantage to the scope of the study, nevertheless they are each presented with their own 
limitations that might affect the study in a different dynamic and may alter the end result in 
some form. 
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Appendix B: Reagents Lists 
Table 8: Regularly used reagents and substances. 
Reagents Manufacturer 
2-Mercaptoethanol  Sigma-Aldrich, USA 
Acrylamide solution 40%  Sigma-Aldrich, USA 
Ammonium persulfate–APS  Sigma-Aldrich, USA 
Bromophenol Blue  Sigma-Aldrich, USA 
Ethanol  Sigma-Aldrich, USA 
Potassium chloride – KCl  Merck- Calbiochem, USA 
Methanol  Merck-Millipore, USA 
MgCl2– Magnesium chloride  Merck- Calbiochem, USA 
N,N,N′,N′-Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, USA 
Ponceau S  Sigma-Aldrich, USA 
Sodium acetate  Sigma-Aldrich, USA 
Sodium chloride –NaCl  Merck- Calbiochem, USA 
Sodium Dodecyl Sulphate (SDS)  Sigma-Aldrich, USA 
Tween 20™  Sigma-Aldrich, USA 
Trypsin Sigma-Aldrich, USA 
Hydrochloric acid 32% - HCl  Merck- Millipore, USA 
  
Table 9: Sample Loading Buffer (2X). 
Reagents Concentration 
dH2O 1.75 mL 
1M Tris-HCL, pH6.8 1.25 mL 
10% SDS 4 mL 
Glycerol 2 mL 
Bromophenol blue 0.05 mg 
β-mercaptoethonol  1 mL 
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Appendix C: Negative controls microrheology (MPTM) 
Negative controls used for MPTM testing was performed to determine the presence or 
absence of MitoTracker in the cell culture plates. For our control no MitoTracker was added, 
as observed below there is no green fluorescence visible, indicated by the red arrows. 
WM1158 
SK-MEL29 
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Appendix D: Melting Peak Analysis of Primers for qRT-PCR 
 
 
A) Line chart illustrating the melting peaks for the target gene (Actin) and the housekeeping 
gene (GUSB) Melting curve analysis for both WM1158 and SK-MEL29 cell lines is 
summarised with single melting peaks are observed for both GUSB and ACTC1 primers 
assayed, indicating high specificity. B) Line chart illustrating the melting peaks for the target 
gene (β-Tubulin), by representing the different cell line conditions by the different colours. 
Melting curve analysis for both WM1158 and SK-MEL29 cell lines is summarised with single 
melting peak was observed for TUBB primer assayed, also indicating high specificity. The melt 
peak describes the temperature at which the synthesized DNA fragment denatures from the 
cDNA template, representing the melting temperature Tm of the double stranded DNA 
product. The temperature is plotted against the negative regression of fluorescence, - (d/dT). 
 
 
